Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Lilly and Adocia have announced a new worldwide licensing collaboration, focused on developing an ultra-rapid insulin known as BioChaperone Lispro.
Based on Adocia's proprietary BioChaperone technology, the drug is currently in phase Ib testing and has shown potential in optimising glucose levels during and after meals for patients with type 1 and 2 diabetes.
https://www.zenopa.com/news/8017678...vely-develop-new-insulin-therapy-for-diabetes
Based on Adocia's proprietary BioChaperone technology, the drug is currently in phase Ib testing and has shown potential in optimising glucose levels during and after meals for patients with type 1 and 2 diabetes.
https://www.zenopa.com/news/8017678...vely-develop-new-insulin-therapy-for-diabetes